Bedaquiline resistance pattern in clofazimine-resistant clinical isolates of tuberculosis patients

• DOI: 10.1016/j.jgar.2023.04.003
• Publication Date: 2023-05-03T06:03:31Z
• Authors: Yuanyuan Shang; Suting Chen; Wenhui Shi; Wenjuan Nie; Wei Jing; Fengmin Huo; Yi Xue; Lingling Dong; Guanglu Jiang; Hairong Huang; Naihui Chu
• Keywords: Bedaquiline; Clofazimine; Cross-resistance

Bedaquiline (BDQ) is a potent drug for treating drug-resistant tuberculosis (TB). Here, we analysed the resistance profiles of BDQ in CFZ-resistant clinical isolates and investigated risk factors CFZ cross/co-resistance.The AlarmarBlue microplate assay was performed to determine minimum inhibitory concentration (MIC) Mycobacterium (MTB) BDQ. The characteristics respective patients were explore possible resistance. drug-resistance-associated genes including Rv0678, Rv1979c, atpE, pepQ Rv1453 sequenced analysed.A total 72 MTB collected; among these, half identified as BDQ-resistant. MIC value closely correlated with (Spearman's q = 0.766, P < 0.005). Among ≥4 mg/L, 92.31% (12/13) resistant Pre-XDR exposure or are major concurrent 36 cross/co-resistant isolates, 50% (18/36) had mutations 8.3% (3/36) Rv0678+Rv1453, 5.6% (2/36) Rv0678+Rv1979c, 2.8% (1/36) Rv0678+Rv1979c+Rv1453, atpE+Rv0678+Rv1453, 27.7% (10/36) no variations target genes.Nearly still sensitive BDQ, whereas this rate dramatically decreased pre-XDR TB those who been exposed CFZ.